<DOC>
	<DOCNO>NCT02186145</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety association metronidazole , nystatin dexamethasone treatment bacterial fungal vaginal infection .</brief_summary>
	<brief_title>Efficacy Safety Study Metronidazole , Nystatin Dexamethasone Combination Therapy Bacterial Fungal Vaginal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<criteria>Postmenarche woman premenopausal woman , 18 50 year old ; Diagnosis bacterial vaginosis ( Amsel criterion ) , fungal ( positive KOH test ) mix vaginal infection ; Patients regular menstrual cycle ( patient regular menstrual cycle interval 21 35 day , duration 1 7 day ) Patients know hypersensitivity component formula ; Pregnant lactate woman ; Patients vaginal infection , infection Trichomonas vaginalis , C. trachomatis , Neisseria gonorrhoeae , herpes HPV . Knowledge positive test result human immunodeficiency virus ; Patients treatment cervical intraepithelial neoplasia carcinoma cervix ; Patients undergone gynecological procedure month prior inclusion ( cauterization cervix , cervical biopsy , highfrequency surgery ) ; Patients vaginal vulvar condition may confound interpretation clinical response ; Patients receive intravaginal systemic antimicrobial antifungal therapy 14 day randomization ; Patients immunosuppressive medication ( corticosteroid , cyclosporine , etc . ) ; Known suspected cancer ; Participation experimental study ingestion experimental drug 12 month start study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>